Medicaid Bulletin
SPECIAL BULLETIN COVID-19 #139: COVID-19 Temporary Provider Rate Increases and Clinical Policy Changes Extended
Consistent with the federal Department of Health and Human Services’ extension of the federal COVID-19 Public Health Emergency to January 21, 2021, NC Medicaid is extending COVID-19 temporary provider rate increases and clinical coverage policies to that same date.
Updates to Clinical Coverage Policy 5A-3, Nursing Equipment and Supplies
All temporary Durable Medical Equipment (DME) policy flexibilities outlined in COVID-19 Special Bulletins remain in effect. An amended version of Clinical Coverage Policy 5A-3, Nursing Equipment and Supplies with an effective date of Oct. 1, 2020, was posted to the NC Medicaid Clinical Coverage Policy web page.
Updates to Clinical Coverage Policy 5A-2, Respiratory Equipment and Supplies
All temporary Durable Medical Equipment (DME) policy flexibilities outlined in COVID-19 Special Bulletins remain in effect. An amended version of Clinical Coverage Policy 5A-2, Respiratory Equipment and Supplies with an effective date of Oct. 1, 2020, was posted to the NC Medicaid Clinical Coverage Policy web page.
Viltolarsen Injection, for Intravenous Use (Viltepso™) HCPCS Code J3490: Billing Guidelines
Effective with date of service Aug. 20, 2020, the Medicaid and NC Health Choice programs cover viltolarsen injection, for intravenous use (Viltepso™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3490 - Unclassified drugs.
Satralizumab-mwge Injection, for Subcutaneous Use (Enspryng™) HCPCS Code J3590: Billing Guidelines
Effective with date of service Aug. 24, 2020, the NC Medicaid and NC Health Choice programs cover satralizumab-mwge injection, for subcutaneous use (Enspryng™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3590 - Unclassified biologics.
Infliximab-axxq for Injection, for Intravenous use (Avsola™) HCPCS code Q5121: Billing Guidelines
Effective with date of service Sept. 11, 2020, the Medicaid and NC Health Choice programs cover infliximab-axxq for injection, for intravenous use (Avsola) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code Q5121 - Injection, infliximab-axxq, biosimilar, (avsola), 10 mg.
Belantamab Mafodotin-blmf for injection, for Intravenous use (Blenrep™) HCPCS Code J9999: Billing Guidelines
Effective with date of service Aug. 6, 2020, the Medicaid and NC Health Choice programs cover belantamab mafodotin-blmf for injection, for intravenous use (Blenrep™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.
SPECIAL BULLETIN COVID-19 #138: New Opportunity for Providers Applying for Federal Relief Funds and Additional Guidance
The US Department of Health and Human Services announced an additional funding opportunity for Medicaid/CHIP providers to apply for federal Provider Relief Funds. The application period runs through Nov. 6, 2020.
NC Medicaid Electronic Health Record Incentive Program Announcements
NC-MIPS is Open for Program Year 2020, Program Year 2020 Webinar Series, The Security Risk Analysis (SRA) and Program Year 2021 Announcements.
Clinical Coverage Policies
The following new or amended clinical coverage policies are available on the Clinical Coverage Policies web page on NC Medicaid’s website.
Medicaid Bulletin Monthly Digest
Articles beginning January 2018 are available in the blog format.
Share this page: